Antitumor effects of the immunoconjugate composed of adriamycin and monoclonal antibody Endoglin.

Objective To study the antitumor effects of an immunoconjugate composed of adriamycin(ADM) and anti-Endoglin monoclonal antibody(mAb) END.Methods END-ADM immunoconjugate was constructed using m-Maleimidobenzoyl-N-hydroxysuccinimide ester(MBS).The cytotoxicity of the conjugate was examined by MTT assay.Antitumor effects of the conjugate was evaluated in vivo in mice bearing subcutaneously-injected H22 tumor.The candidate drugs were administered intravenously.Results There was no significant difference in cytotoxicity between END-ADM and free ADM.However,free ADM inhibited the growth of H22 by 29.3% on day 14 at the dose of 0.4 mg/kg in vivo,while the equivalent dose of END-ADM conjugate reached 86.6% with significant difference(P0.05).Meanwhile,END-ADM significantly elongated median survival time,when comparing with free ADM treatment(P0.05).Conclusion END-ADM provides significantly more prominent antitumor effects than free ADM in vivo and is suggested to be a novel candidate for cancer treatment.